# Singlera Genomics

Source: https://onco.cc/companies/singlera/  
OnCo record `singlera` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A methylation testing company with laboratories in California and Shanghai that published the PanSeer multi-cancer blood test.

## Summary

Singlera Genomics, established in 2014 according to its website, with a La Jolla address and a Shanghai subsidiary, published PanSeer, a five-cancer methylation blood test evaluated on stored samples from the Taizhou Longitudinal Study (Nature Communications 2020). Its website now lists single-cancer colorectal and liver tests; its FuSion cohort with Fudan University and the INSPIRE case-control study develop multi-cancer successors.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: La Jolla, CA
- Type: diagnostics
- Website: https://www.singlera.com/

## Sources

- Official website: https://www.singlera.com/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Cell-free DNA methylation tests](https://onco.cc/technologies/cfdna-methylation-testing/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [PanSeer](https://onco.cc/drugs/panseer/)
- trials: [FuSion (Fudan and Singlera pan-cancer screening cohort)](https://onco.cc/trials/fusion-singlera/), [INSPIRE (Singlera methylation and fragmentomics case-control study)](https://onco.cc/trials/inspire-singlera/)
- key papers: [Non-invasive early detection of cancer four years before conventional diagnosis using a blood test](https://onco.cc/key-papers/paper-panseer-nat-commun-2020/)

---
JSON: https://onco.cc/api/v1/entities/singlera.json